The effect of Lidocaine and its Delivery in Patients with Chronic Cough - Lidocaine: Effect of Lidocaine in Chronic Cough

• Conditions: Chronic Cough

• Registration Number: EUCTR2010-022472-31-GB
• Lead Sponsor: niversity Hospital of South Manchester

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-10-05
• Last Update Posted: 11 September 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 0

Inclusion Criteria

- Male and female subjects, age 18 years and over. - History of cough for more than 8 weeks. - Normal chest x ray. - Chronic idiopathic cough or chronic cough resistant to treatment of specific triggers.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
;
- Male and female subjects, age 18 years and over. - History of cough for more than 8 weeks. - Normal chest x ray. - Chronic idiopathic cough or chronic cough resistant to treatment of specific triggers.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

SMOKING STATUS: - Current smokers - Ex smokers with history of smoking > 20 pack years or those who have given up < 6 months ago. PROHIBITED MEDICATIONS: - Use of medications likely to suppress / affect cough including codeine, morphine, pregabalin, gabapentin, amitriptylline, angiotensin convertin enzyme inhibitors (type 1) and baclofen. - Use of any anti-arrhythmic medication. - Use of cimetidine, beta blockers, or diuretics. CARDIOVASCULAR CONDITIONS: - Sinoatrial disease, bradycardia or all types of heart blocks. - History of ischaemic heart disease or heart failure. - Clinically significant abnormal electrocardiogram (ECG) at Screening or Baseline. - History of cardiac surgery RESPIRATORY CONDITIONS: - Asthma. CENTRAL/PERIPHERAL NERVOUS SYSTEM CONDITIONS: - Epilepsy. - Myasthenia gravis. MISCELLANEOUS: - History of hepatic or renal dysfunction. - Porphyria - History of hypersensitivity to Lidocaine or related drugs. - Pregnancy or breast feeding. - Participation in another trial within the preceding 6 weeks. - Trauma or ulceration to oral mucosa. - History of chest or upper airway infection within the past 6 weeks. - Conditions which may affect cough response such as stroke, diabetes, Parkinson’s disease.
;
SMOKING STATUS: - Current smokers - Ex smokers with history of smoking > 20 pack years or those who have given up < 6 months ago. PROHIBITED MEDICATIONS: - Use of medications likely to suppress / affect cough including codeine, morphine, pregabalin, gabapentin, amitriptylline, angiotensin convertin enzyme inhibitors (type 1) and baclofen. - Use of any anti-arrhythmic medication. - Use of cimetidine, beta blockers, or diuretics. CARDIOVASCULAR CONDITIONS: - Sinoatrial disease, bradycardia or all types of heart blocks. - History of ischaemic heart disease or heart failure. - Clinically significant abnormal electrocardiogram (ECG) at Screening or Baseline. - History of cardiac surgery RESPIRATORY CONDITIONS: - Asthma. CENTRAL/PERIPHERAL NERVOUS SYSTEM CONDITIONS: - Epilepsy. - Myasthenia gravis. MISCELLANEOUS: - History of hepatic or renal dysfunction. - Porphyria - History of hypersensitivity to Lidocaine or related drugs. - Pregnancy or breast feeding. - Participation in another trial within the preceding 6 weeks. - Trauma or ulceration to oral mucosa. - History of chest or upper airway infection within the past 6 weeks. - Conditions which may affect cough response such as stroke, diabetes, Parkinson’s disease.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified